QUEST DIAGNOSTICS INC 8-K

What Happened

• Quest Diagnostics (DGX) filed an 8‑K on May 21, 2026 reporting outcomes of its Annual Meeting held May 20, 2026. All board nominees were elected for terms expiring at the 2027 Annual Meeting. Votes on executive compensation, the independent auditor, and a stockholder proposal on an independent board chair were also tallied.
• Director vote totals (selected): all nominees received more FOR than AGAINST votes; FOR votes ranged from about 81,917,543 (Timothy M. Ring) to 93,909,369 (Luis A. Diaz, Jr., M.D.). Several directors drew notable opposition (e.g., Vicky B. Gregg: 83,814,387 FOR, 10,232,574 AGAINST; Timothy M. Ring: 81,917,543 FOR, 11,994,424 AGAINST).

Key Details

• Annual Meeting date: May 20, 2026; 8‑K filed May 21, 2026.
• Say‑on‑pay (advisory vote on executive compensation): Approved — 86,869,738 FOR; 7,152,448 AGAINST; 177,559 ABSTAIN; 9,135,906 non‑votes.
• Auditor ratification: PricewaterhouseCoopers LLP re‑appointed — 97,340,034 FOR; 5,809,995 AGAINST; 185,622 ABSTAIN.
• Stockholder proposal to require an independent board chairman: Not approved — 23,999,636 FOR; 69,792,819 AGAINST; 407,290 ABSTAIN; 9,135,906 non‑votes.

Why It Matters

• These voting outcomes confirm Quest Diagnostics’ board slate and governance priorities for the coming year and maintain continuity in audit oversight with PwC re‑appointed as auditor. The advisory approval of executive pay means shareholders broadly supported the compensation disclosed, though it is non‑binding. The rejection of the independent‑chair proposal indicates shareholders did not mandate a separation of chair/CEO role at this time. Investors should view these as governance and oversight signals rather than changes to operational or financial guidance.